HL Genomics Co. Ltd. (Ticker: 0156T0 KS) is a South Korean pharmaceutical company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and standard materials. The company, headquartered in Yongin, Gyeonggi-do, plans to list on KOSDAQ on July 24, 2026.

According to published terms, HL Genomics priced its IPO at KRW 21,500 per share, at the top of the indicated KRW 18,500–21,500 range, offering 2.57 million shares and raising KRW 55.15 billion, or approximately $37 million. The company’s market capitalization at offer is estimated at approximately $111 million. The offering consists of 1.71 million primary shares, representing 66.67% of the deal, and 855,000 secondary shares, representing 33.33%. KB Securities and IBK Investment Securities are managing the transaction. HL Genomics was founded in 2000 and operates in basic pharmaceutical manufacturing, with a focus on GMP-based quality management and API production for domestic and international pharmaceutical customers.